Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
cosyntropinpræparat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tetracosactide |
Inferred relationship |
Some |
|
Tetracosactrin adverse reaction |
Causative agent |
True |
Tetracosactide |
Inferred relationship |
Some |
1 |
Allergy to tetracosactrin |
Causative agent |
False |
Tetracosactide |
Inferred relationship |
Some |
|
Product containing tetracosactide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tetracosactide |
Inferred relationship |
Some |
1 |
cosyntropin 250 µg/1 ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tetracosactide |
Inferred relationship |
Some |
|
cosyntropin 1 mg/1 ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tetracosactide |
Inferred relationship |
Some |
|
cosyntropin 50 µg + mannitol 10 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tetracosactide |
Inferred relationship |
Some |
|
cosyntropin 25 µg + mannitol 10 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Tetracosactide |
Inferred relationship |
Some |
|
Tetracosactide acetate |
Is a |
False |
Tetracosactide |
Inferred relationship |
Some |
|
Allergy to tetracosactrin |
Causative agent |
True |
Tetracosactide |
Inferred relationship |
Some |
1 |
Tetracosactide acetate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Tetracosactide |
Inferred relationship |
Some |
|
Tetracosactide-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tetracosactide |
Inferred relationship |
Some |
1 |
Tetracosactide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tetracosactide |
Inferred relationship |
Some |
1 |
Tetracosactide only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Tetracosactide |
Inferred relationship |
Some |
1 |
Tetracosactide (as tetracosactide acetate) 250 microgram/mL solution for injection |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Tetracosactide |
Inferred relationship |
Some |
1 |